PHARMACEUTICAL COMPOSITION COMPRISING [E]-N[5-[2-[2-[2,4-DIHYDROXYBENZYLIDENE]HYDRAZINYL]-2-OXOETHYL]-1, 3, 4-THIADIAZOL-2-YL]-4-METHOXYBENZAMIDE FOR PREVENTING AND TREATING OF NEURODEGENERATIVE DISEASE
PARK, SANG ICK,박상익,KIM, HYUN YOUNG,김현영,LEE, SUK KYUNG,이숙경
申请号：
KR1020120071710
公开号：
KR1012294300000B1
申请日:
2012.07.02
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: A pharmaceutical composition containing (E)-N-(5-(2-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-2-oxoethyl)-1,3,4-thiadiazol-2-yl)-4-methoxybenzamide for preventing and treating neurodegenerative diseases is provided to specifically suppress an S1 pocket of GCP II and to prevent and treat Alzheimer's disease. CONSTITUTION: A pharmaceutical composition for preventing and treating Alzheimer's disease, Parkinson's disease, amylotrophic lateral scelerosis(ALS), or dementia contains (E)-N-(5-(2-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-2-oxoethyl)-1,3,4-thiadiazol-2-yl)-4-methoxybenzamide of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The compound of chemical formula 1 specifically suppresses an S1 pocket of GCP II(glutamate carboxypeptidase II) and strengthens synapses at an early phase.본 발명은 (E)-N-(5-(2-(2-(2,4-다이히드록시벤질리덴)히드라지닐)-2-옥소에틸)-1,3,4-티아디아졸-2-일)-4-에틸벤즈아마이드((E)-N-(5-(2-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-2-oxoethyl)-1,3,4-thiadiazol-2-yl)-4-ethylbenzamide) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명에 따른 화합물은 GCPⅡ의 S1 포켓을 특이적으로 억제하여 Aβ의 분해를 억제함으로써, 시냅스 강화가 일어나며, 질환의 진행 단계에 따라 Aβ의 항상성 유지에 중요한 역할을 할 수 있어 알츠하이머 질환의 예방 및 치료용 약학적 조성물로 유용하게 이용될 수 있다.
